A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation
Patient entry is now complete in a prospective trial of anti-Tac, a murine IgG2a monoclonal antibody directed against the p55 chain of the human IL-2 receptor, for the prevention of renal allograft rejection. Recipients of primary cadaver allografts were randomized to receive either anti-Tac (20 mg...
Saved in:
Published in | Transplantation Vol. 51; no. 1; p. 107 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.01.1991
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Patient entry is now complete in a prospective trial of anti-Tac, a murine IgG2a monoclonal antibody directed against the p55 chain of the human IL-2 receptor, for the prevention of renal allograft rejection. Recipients of primary cadaver allografts were randomized to receive either anti-Tac (20 mg q.d. x 10 days beginning POD 1) plus low-dose CsA (4 mg/kg/day), azathioprine (2 mg/kg/day), and prednisone (30 mg q.d.), or conventional triple therapy with CsA (8 mg/kg/day), azathioprine, and prednisone. Forty patients were entered in each group, with current followup from 6 to 26 months. The results show a significant reduction in early rejection episodes in the anti-Tac-treated patients. During the 10-day treatment, 5 of 40 anti-Tac patients had rejection episodes, compared with 21 of 40 control patients (P less than 0.001). Anti-Tac significantly delayed the time to the first rejection (12.5 +/- 6.3 vs. 7.6 +/- 6.7 days) (P less than 0.05). Despite these effects, there were no differences in either actual or actuarial graft or patient survival between the two groups. Pneumonia, primarily CMV, developed in 5 treated and 4 control patients. In patients with functioning grafts mean serum creatinine at 3 months was 1.8 +/- 0.7 in the anti-Tac group and 2.0 +/- 0.8 in the control group (P = NS); at 12 months the values were 2.3 +/- 1.5 and 1.8 +/- 0.5, respectively (P = NS). The peak expression of IL-2 receptors on circulating T-cells was significantly lower in anti-Tac patients (15.1 +/- 3.6%) than in controls (21.9 +/- 4.5%) (P less than 0.05). Seven of 10 patients tested to date developed antimouse immunoglobulin antibodies, with antiidiotype shown in 6. These antibodies do not preclude subsequent treatment with OKT3. Five patients in this and previous anti-Tac protocols have received OKT3 for acute rejection despite known pretreatment antimouse antibodies, with resolution of rejection in all cases. |
---|---|
AbstractList | Patient entry is now complete in a prospective trial of anti-Tac, a murine IgG2a monoclonal antibody directed against the p55 chain of the human IL-2 receptor, for the prevention of renal allograft rejection. Recipients of primary cadaver allografts were randomized to receive either anti-Tac (20 mg q.d. x 10 days beginning POD 1) plus low-dose CsA (4 mg/kg/day), azathioprine (2 mg/kg/day), and prednisone (30 mg q.d.), or conventional triple therapy with CsA (8 mg/kg/day), azathioprine, and prednisone. Forty patients were entered in each group, with current followup from 6 to 26 months. The results show a significant reduction in early rejection episodes in the anti-Tac-treated patients. During the 10-day treatment, 5 of 40 anti-Tac patients had rejection episodes, compared with 21 of 40 control patients (P less than 0.001). Anti-Tac significantly delayed the time to the first rejection (12.5 +/- 6.3 vs. 7.6 +/- 6.7 days) (P less than 0.05). Despite these effects, there were no differences in either actual or actuarial graft or patient survival between the two groups. Pneumonia, primarily CMV, developed in 5 treated and 4 control patients. In patients with functioning grafts mean serum creatinine at 3 months was 1.8 +/- 0.7 in the anti-Tac group and 2.0 +/- 0.8 in the control group (P = NS); at 12 months the values were 2.3 +/- 1.5 and 1.8 +/- 0.5, respectively (P = NS). The peak expression of IL-2 receptors on circulating T-cells was significantly lower in anti-Tac patients (15.1 +/- 3.6%) than in controls (21.9 +/- 4.5%) (P less than 0.05). Seven of 10 patients tested to date developed antimouse immunoglobulin antibodies, with antiidiotype shown in 6. These antibodies do not preclude subsequent treatment with OKT3. Five patients in this and previous anti-Tac protocols have received OKT3 for acute rejection despite known pretreatment antimouse antibodies, with resolution of rejection in all cases. |
Author | Shapiro, M E Kirkman, R L Strom, T B Milford, E L Ramos, E L Carpenter, C B Zimmerman, C E McKay, D B Waldmann, T A Tilney, N L |
Author_xml | – sequence: 1 givenname: R L surname: Kirkman fullname: Kirkman, R L organization: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 – sequence: 2 givenname: M E surname: Shapiro fullname: Shapiro, M E – sequence: 3 givenname: C B surname: Carpenter fullname: Carpenter, C B – sequence: 4 givenname: D B surname: McKay fullname: McKay, D B – sequence: 5 givenname: E L surname: Milford fullname: Milford, E L – sequence: 6 givenname: E L surname: Ramos fullname: Ramos, E L – sequence: 7 givenname: N L surname: Tilney fullname: Tilney, N L – sequence: 8 givenname: T A surname: Waldmann fullname: Waldmann, T A – sequence: 9 givenname: C E surname: Zimmerman fullname: Zimmerman, C E – sequence: 10 givenname: T B surname: Strom fullname: Strom, T B |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/1846250$$D View this record in MEDLINE/PubMed |
BookMark | eNotj91qAyEQhaWkpEnaRyj4ArajrrpehtA_CPQmvSzBdV1q2dXFNYX06evSDAzDfDPnwFmjRYjBIYQpPFDQ6hFKqVoDoVpToGUjpam8QisqeEUk1LBAK4CKEsq5ukHrafouL4IrtURLWleSCVihzy1OJrRx8L-uxWOK0-hs9j8O5-RNj2OHTcieHIzFQwzR9jEUPLMmtmfsA_46DSbg5Gaei9k09uVsso_hFl13pp_c3WVu0Mfz02H3SvbvL2-77Z5YriETKWquOyttazQYYyy1dcdm0kEjRcdlJSrXStsoxqwVgmnGS3BX1I4BZRt0_-87nprBtccx-cGk8_ESk_0Bnu9ZBQ |
CitedBy_id | crossref_primary_10_1097_00007890_199901270_00016 crossref_primary_10_1016_S0025_7753_01_72044_1 crossref_primary_10_2165_00063030_200115100_00003 crossref_primary_10_1016_S0039_6109_05_70007_4 crossref_primary_10_1016_0167_5699_93_90043_K crossref_primary_10_1016_S0955_470X_10_80006_0 crossref_primary_10_1111_j_1349_7006_1998_tb00582_x crossref_primary_10_1097_00075200_199912000_00005 crossref_primary_10_1111_j_1432_2277_1994_tb01442_x crossref_primary_10_1016_S0140_6736_97_09278_7 crossref_primary_10_7326_0003_4819_116_2_148 crossref_primary_10_1111_j_1600_6143_2005_01075_x crossref_primary_10_1016_j_ijt_2014_06_001 crossref_primary_10_1046_j_1365_2249_2001_01487_x crossref_primary_10_1016_0952_7915_91_90104_9 crossref_primary_10_1016_0167_5699_91_90030_W crossref_primary_10_1517_13543784_5_5_555 crossref_primary_10_1016_0734_9750_93_90001_4 crossref_primary_10_1002_1097_0142_19950401_75_7_1598__AID_CNCR2820750708_3_0_CO_2_7 crossref_primary_10_1517_14656566_1_7_1307 crossref_primary_10_1007_BF02063943 crossref_primary_10_1016_0022_1759_95_00131_S crossref_primary_10_1016_S0749_0704_02_00051_9 crossref_primary_10_1097_00007890_199802150_00020 crossref_primary_10_1007_BF02171733 crossref_primary_10_1016_j_transproceed_2004_01_049 crossref_primary_10_1016_j_atc_2004_06_009 crossref_primary_10_1016_j_transproceed_2005_01_071 crossref_primary_10_2165_00063030_200013060_00003 crossref_primary_10_1592_phco_19_15_1127_30582 crossref_primary_10_1016_S0272_6386_96_90297_8 crossref_primary_10_1046_j_1523_1755_1999_00373_x crossref_primary_10_1038_ki_1997_176 crossref_primary_10_1034_j_1600_6143_2002_20612_x crossref_primary_10_1016_S0041_1345_98_01976_9 crossref_primary_10_1002_eji_1830230434 crossref_primary_10_1016_1050_1738_93_90006_R crossref_primary_10_1016_S0039_6109_05_70636_8 crossref_primary_10_1097_00007890_199602270_00006 crossref_primary_10_1016_S0953_7112_05_80139_5 crossref_primary_10_1016_S0140_6736_98_07493_5 crossref_primary_10_1038_ki_1994_306 crossref_primary_10_1097_00007890_199701150_00007 crossref_primary_10_1016_0735_1097_93_90815_I crossref_primary_10_1016_S0041_1345_01_02914_1 crossref_primary_10_1111_j_1432_2277_1992_tb01753_x crossref_primary_10_1034_j_1600_6143_2002_020107_x crossref_primary_10_1097_01_TP_0000109643_32659_C4 crossref_primary_10_1016_0966_3274_95_80026_3 crossref_primary_10_1097_01_mpg_0000172260_46986_11 crossref_primary_10_1111_j_1432_2277_1996_tb00851_x crossref_primary_10_1016_S0041_1345_98_01529_2 crossref_primary_10_1038_nri1901 crossref_primary_10_1111_tri_1992_5_s1_444 crossref_primary_10_1093_ndt_14_12_2824 crossref_primary_10_1111_j_1600_065X_1992_tb01417_x crossref_primary_10_4161_mabs_2_2_11159 crossref_primary_10_1517_13543784_5_1_49 crossref_primary_10_1016_S0952_7915_98_80215_X crossref_primary_10_1111_j_1432_2277_1998_tb00798_x crossref_primary_10_1517_14712598_7_10_1583 crossref_primary_10_1007_s00281_006_0014_7 crossref_primary_10_1097_00007890_199607150_00011 crossref_primary_10_1016_j_transproceed_2003_09_098 crossref_primary_10_1016_j_transproceed_2008_02_029 crossref_primary_10_1016_S0899_5885_18_30651_8 crossref_primary_10_1586_1744666X_1_3_337 crossref_primary_10_1586_14787210_2014_917046 crossref_primary_10_1002_14651858_CD003897_pub3 crossref_primary_10_1016_0162_3109_95_00028_R crossref_primary_10_1016_S0041_1345_00_02310_1 crossref_primary_10_1016_S0039_6109_16_46432_7 crossref_primary_10_1016_S0041_1345_96_00283_7 crossref_primary_10_1097_00007890_199706270_00012 crossref_primary_10_1097_00007890_199712270_00012 crossref_primary_10_1111_j_1600_065X_1992_tb01422_x crossref_primary_10_1097_00007890_200205270_00020 crossref_primary_10_1097_01_tp_0000234905_56926_7f crossref_primary_10_1097_00007890_199707270_00017 crossref_primary_10_1111_j_1432_2277_2000_tb01056_x crossref_primary_10_1016_S0041_1345_98_00571_5 crossref_primary_10_1007_BF01541085 crossref_primary_10_1016_0165_6147_93_90201_T crossref_primary_10_1056_NEJM199801153380304 crossref_primary_10_1016_j_athoracsur_2003_07_006 crossref_primary_10_1097_00007890_199901150_00019 crossref_primary_10_1016_S0041_1345_02_03487_5 crossref_primary_10_1097_00007890_199903270_00014 crossref_primary_10_1111_j_1440_1797_1996_tb00060_x crossref_primary_10_1097_00007890_200301150_00007 crossref_primary_10_1097_00007890_200002270_00005 crossref_primary_10_1111_j_1440_1681_2006_04396_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/00007890-199101000-00016 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1534-6080 |
ExternalDocumentID | 1846250 |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: N01-AI-82512 |
GroupedDBID | --- -~X .-D .55 .GJ .XZ .Z2 01R 0R~ 123 1J1 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AAUEB AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPPZ ABVCZ ABXVJ ABZAD ACBNA ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFDTB AFEXH AFFNX AFSOK AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJIOK AJNWD AJNYG AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BOYCO BQLVK BS7 C45 CGR CS3 CUY CVF D0S DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IH2 IKREB IKYAY IN~ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B MVM N9A NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA ODMTH OHT OHYEH OJAPA OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YOC ZA5 ZFV ZGI ZXP ZZMQN |
ID | FETCH-LOGICAL-c390t-65839fc6cda90aaac1c8f29fc6f0b65f36454ed6cb722cc552923991e390e2012 |
ISSN | 0041-1337 |
IngestDate | Thu May 23 23:54:12 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c390t-65839fc6cda90aaac1c8f29fc6f0b65f36454ed6cb722cc552923991e390e2012 |
OpenAccessLink | https://doi.org/10.1097/00007890-199101000-00016 |
PMID | 1846250 |
ParticipantIDs | pubmed_primary_1846250 |
PublicationCentury | 1900 |
PublicationDate | 1991-Jan |
PublicationDateYYYYMMDD | 1991-01-01 |
PublicationDate_xml | – month: 01 year: 1991 text: 1991-Jan |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Transplantation |
PublicationTitleAlternate | Transplantation |
PublicationYear | 1991 |
SSID | ssj0005377 |
Score | 1.748235 |
Snippet | Patient entry is now complete in a prospective trial of anti-Tac, a murine IgG2a monoclonal antibody directed against the p55 chain of the human IL-2 receptor,... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 107 |
SubjectTerms | Adolescent Adult Animals Antibodies, Anti-Idiotypic - analysis Antibodies, Monoclonal - therapeutic use Cytomegalovirus Infections - etiology Female Graft Rejection Graft Survival Humans Kidney Transplantation - adverse effects Kidney Transplantation - mortality Male Mice Mice, Inbred BALB C Middle Aged Prospective Studies Receptors, Interleukin-2 - analysis Receptors, Interleukin-2 - immunology |
Title | A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/1846250 |
Volume | 51 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8NAFB6qongRV9yZg3gpI8lkPxZRilIPWsGLyGQWrNqkSDzoP_Bf-2ZJG6ricglhhoQk78ubecv3HkIHgFnhww9NAkUjEkpfEZaqnCRSCeWziArj7-hdxN3r8Owmumm13htZSy9VfsTfvuSV_EeqMAZy1SzZP0h2fFMYgHOQLxxBwnD8lYw7bVhpRDkcvEnN9i9r2mTb9uLQIf6iGpA-4214ppI_GbefHstLYQh_tkXfs7Q557rO-RMrGtH5h8aKNjVlAvfPj86Detkee5Gv7tloYOkzvQbRQQd6CtcGpNHsucfPmY3kuzHhOHl-wwXh1GroEzB27copa00aktizbZpqVRv5nyBl9aZrfftJn9s6wSbemmaezooBFeLI8Jaj2RDzaGjkDDYrGHXej5NTdbbdzAyaSVKtKi-026fOFQoSW3zVvadLCaurf371bIto3t1xymAxG5f-MlpyFgfuWPisoJYsVtFap2BVOXzFh9jkAJvgyipa6LlUizV028ETcOEGuLABFy4VrsGFJ-DCNbjwoMAGXNiAC0-Bax1dn570j7vE9eIgPMi8isBGNcgUj7lgmccY4z5PFdUjysvjSOlodihFzPOEUs6jiGaaNe1LuFrCJpNuoNmiLOQmwpTxSApPBjTJYfueZzETSaC4ClPJZKi20Ib9XncjW3Dlzn3I7e8mdtDiBJa7aE7B_y33YLNY5ftGkB_eF2Xs |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized+prospective+trial+of+anti-Tac+monoclonal+antibody+in+human+renal+transplantation&rft.jtitle=Transplantation&rft.au=Kirkman%2C+R+L&rft.au=Shapiro%2C+M+E&rft.au=Carpenter%2C+C+B&rft.au=McKay%2C+D+B&rft.date=1991-01-01&rft.issn=0041-1337&rft.eissn=1534-6080&rft.volume=51&rft.issue=1&rft.spage=107&rft_id=info:doi/10.1097%2F00007890-199101000-00016&rft_id=info%3Apmid%2F1846250&rft_id=info%3Apmid%2F1846250&rft.externalDocID=1846250 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1337&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1337&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1337&client=summon |